What does FIDELMED do?

FIDELMED is a wholesaler in Gent. Public Limited, started on 28 June 2018, 1 establishment.

What is the address of FIDELMED?

The registered office of FIDELMED is located at Waalkens 11 box B, 9030 Gent.

Is FIDELMED still active?

Yes. According to the CBE (29 October 2026) FIDELMED is active, legal situation “Normale toestand”, started on 28 June 2018.

Is FIDELMED registered on Peppol?

Yes, FIDELMED is registered on the Peppol network with ID 0208:0698912120.

What is the enterprise number of FIDELMED?

The enterprise number of FIDELMED is BE0698912120.

When was FIDELMED founded?

FIDELMED was founded on 28 June 2018.

Who are the directors of FIDELMED?

According to the 2025 annual accounts, the directors of FIDELMED are: Mediaxe BV, SPIDERWEB BV, BENOVITY BV, Decura Pharma BV.

Is FIDELMED a reliable company?

Databakkes does not pass judgement; this is what the sources say: Active according to the CBE since 28 June 2018; 5 annual accounts filed, latest fiscal year 2025; 4 directors known from the annual account.

How much profit did FIDELMED make in 2025?

FIDELMED recorded a loss after taxes of € 1,662,625 in financial year 2025.

What is the revenue of FIDELMED?

As a small company, FIDELMED is not required to publish revenue in its annual accounts. In financial year 2025, its added value was € -1,325,820.

How much does an employee at FIDELMED earn?

The average wage cost per full-time employee at FIDELMED was € 62,600 in 2025: staff costs of € 206,561 for 3.3 FTE, according to the annual account at the National Bank. That is the employer's cost, not net pay.

How many employees does FIDELMED have?

According to the 2025 annual accounts, FIDELMED has 3.3 full-time equivalents (FTE).

FIDELMED (Public Limited) - Gent - BE0698912120

Dossier FIDELMED, printed on 29 October 2026 from databakkes.be/en/0698912120/fidelmed. Sources: CBE, National Bank of Belgium, Belgian Official Gazette.

Warning lights

Signals from the annual accounts, the CBE and the Official Gazette, each with its threshold and source. No score, no verdict.

Two loss years in a row NBB

Negative result in 2024 and 2025.

Financials

Financial year 2025

FIDELMED from Gent, company number BE0698912120, closed financial year 2025 with a result of € -1.7 million after tax. For that financial year FIDELMED recorded a gross margin of € -1.3 million and equity of € 636,115. Compared with financial year 2024, the result moved from € -1.4 million to € -1.7 million. The company made a loss. The buffer is growing. Debts are under control. The most recent annual accounts were filed with the National Bank of Belgium on July 23, 2026.

What it is worth Growing

€ 636,115

▲ € 904,528 vs 2024

Assets minus debts, by the books. What is left if everything were sold and paid today.

Loss Caution

€ -1.7 million

▼ 19 % more loss than in 2024

Profit after tax over the fiscal year.

Cash in the bank

€ 421,418

▲ € 321,066 vs 2024

Cash and bank balances on the last day of the fiscal year.

Where the profit goes Caution

Loss, nothing to pay out

Reserves fell to € -4.9 million.

People and assets in 2025

Full-time equivalents

3.3

▲ 1.4 vs 2024

Average over the fiscal year, from the social balance sheet.

Wage cost

€ 206,561

▲ 143% vs 2024

€ 62,600 per full-time equivalent. Payroll staff only. What the director pays themselves is already netted into the gross margin and is not shown separately in the accounts.

Vehicles and equipment

€ 8,333

▼ 30% vs 2024

Book value of vehicles, furniture and equipment.

Debts at end 2025

Bank debt ≈ 4 years to go The accounts give the long-term loan and the part due within the year. The remainder divided by that part is the number of years at an equal pace; a new loan or early repayment changes it.

€ 846,960

▼ 38% vs 2024

€ 193,438 is repaid this year. At this pace the long-term loan is gone in ≈ 4 years.

Owed to suppliers

€ 1.5 million

▲ 93% vs 2024

Supplier invoices still open on the last day of the fiscal year.

Taxes and wages

€ 36,298

▲ 110% vs 2024

Taxes, VAT and social contributions still to pay.

Key figures per fiscal year Download key figures (CSV)
	2022	2023	2024	2025	Change 2024 → 2025
Gross margin	€ -90,421 Gross margin 2022: € -90,421 First fiscal year in the series	€ -459,336 Gross margin 2023: € -459,336 ▼ € 368,915 vs 2022 (€ -90,421) Unfavourable step	€ -1,177,545 Gross margin 2024: € -1,177,545 ▼ € 718,209 vs 2023 (€ -459,336) Unfavourable step	€ -1,325,820 Gross margin 2025: € -1,325,820 ▼ € 148,275 vs 2024 (€ -1,177,545) Unfavourable step	▼ € 148,275
Profit after taxes	€ -333,002 Profit after taxes 2022: € -333,002 First fiscal year in the series	€ -517,229 Profit after taxes 2023: € -517,229 ▼ € 184,227 vs 2022 (€ -333,002) Unfavourable step	€ -1,392,988 Profit after taxes 2024: € -1,392,988 ▼ € 875,759 vs 2023 (€ -517,229) Unfavourable step	€ -1,662,625 Profit after taxes 2025: € -1,662,625 ▼ € 269,637 vs 2024 (€ -1,392,988) Unfavourable step	▼ € 269,637
Equity	€ -594,843 Equity 2022: € -594,843 First fiscal year in the series	€ 1,124,575 Equity 2023: € 1,124,575 ▲ € 1.7 million vs 2022 (€ -594,843) Favourable step	€ -268,413 Equity 2024: € -268,413 ▼ € 1.4 million vs 2023 (€ 1,124,575) Unfavourable step	€ 636,115 Equity 2025: € 636,115 ▲ € 904,528 vs 2024 (€ -268,413) Favourable step	▲ € 904,528
Total debts	€ 1,066,433 Total debts 2022: € 1,066,433 First fiscal year in the series	€ 841,273 Total debts 2023: € 841,273 ▼ 21% vs 2022 (€ 1,066,433) Favourable step	€ 2,623,187 Total debts 2024: € 2,623,187 ▲ 212% vs 2023 (€ 841,273) Unfavourable step	€ 2,433,914 Total debts 2025: € 2,433,914 ▼ 7% vs 2024 (€ 2,623,187) Favourable step	▼ 7%
Cash	€ 63,278 Cash 2022: € 63,278 First fiscal year in the series	€ 881,156 Cash 2023: € 881,156 ▲ € 817,879 vs 2022 (€ 63,278) Favourable step	€ 100,351 Cash 2024: € 100,351 ▼ 89% vs 2023 (€ 881,156) Unfavourable step	€ 421,418 Cash 2025: € 421,418 ▲ € 321,066 vs 2024 (€ 100,351) Favourable step	▲ € 321,066
Retained profit	€ -1,369,843 Retained profit 2022: € -1,369,843 First fiscal year in the series	€ -1,887,072 Retained profit 2023: € -1,887,072 ▼ € 517,229 vs 2022 (€ -1,369,843) Unfavourable step	€ -3,280,061 Retained profit 2024: € -3,280,061 ▼ € 1.4 million vs 2023 (€ -1,887,072) Unfavourable step	€ -4,942,685 Retained profit 2025: € -4,942,685 ▼ € 1.7 million vs 2024 (€ -3,280,061) Unfavourable step	▼ € 1.7 million
Bank debt	€ 22,469 Bank debt 2022: € 22,469 First fiscal year in the series	€ 336,398 Bank debt 2023: € 336,398 ▲ € 313,928 vs 2022 (€ 22,469) Unfavourable step	€ 1,364,180 Bank debt 2024: € 1,364,180 ▲ € 1 million vs 2023 (€ 336,398) Unfavourable step	€ 846,960 Bank debt 2025: € 846,960 ▼ 38% vs 2024 (€ 1,364,180) Favourable step	▼ 38%
Balance sheet total	€ 471,590 Balance sheet total 2022: € 471,590 First fiscal year in the series	€ 1,965,848 Balance sheet total 2023: € 1,965,848 ▲ € 1.5 million vs 2022 (€ 471,590) Unchanged	€ 2,354,774 Balance sheet total 2024: € 2,354,774 ▲ 20% vs 2023 (€ 1,965,848) Unchanged	€ 3,070,029 Balance sheet total 2025: € 3,070,029 ▲ 30% vs 2024 (€ 2,354,774) Unchanged	▲ 30%
Employees (FTE)	1 Employees (FTE) 2022: 1 First fiscal year in the series	0.1 Employees (FTE) 2023: 0.1 ▼ 0.9 vs 2022 (1) Unchanged	1.9 Employees (FTE) 2024: 1.9 ▲ 1.8 vs 2023 (0.1) Unchanged	3.3 Employees (FTE) 2025: 3.3 ▲ 1.4 vs 2024 (1.9) Unchanged	▲ 1.4

Key figures of FIDELMED, fiscal years 2022 to 2025, from the annual accounts filed with the National Bank of Belgium.Next annual account (fiscal year 2026) expected before 31 July 2027.

What happened to FIDELMED?

What happened at FIDELMED in recent years, according to the Belgian Official Gazette, the CBE and the National Bank:

2027 Mediaxe BV stepped down as director. NBB
2027 SPIDERWEB BV stepped down as director. NBB
2027 BENOVITY BV stepped down as director. NBB
2027 Decura Pharma BV stepped down as director. NBB
Jul 23, 2026 New annual accounts for financial year 2025: loss of € 1.7 million. Source: NBB ↗
2025 BENOVITY BV became a director. NBB
2023 Mediaxe BV became a director. NBB
Jun 28, 2018 New establishment in Gent. KBO

In short

From € 333,002 loss in 2022 to € 1.7 million loss in 2025.

Paid € 2,859 in corporate taxes since 2022.

Original PDFs at the National Bank ↗

Management

DECURA PHARMA 50%

VALERUS 0.9%

Edson Law

The stake of DECURA PHARMA, VALERUS, Edson Law comes from that shareholder’s own annual accounts; small companies do not report their shareholders themselves.

FIDELMED

PHARMA FIDELMED 100%

The shares are held by DECURA PHARMA (50%), VALERUS (0.9%) and Edson Law. It owns 100% of PHARMA FIDELMED itself.